<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950820</url>
  </required_header>
  <id_info>
    <org_study_id>AIO KRK 0107</org_study_id>
    <nct_id>NCT00950820</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer</brief_title>
  <acronym>VOXEL</acronym>
  <official_title>An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this interventional study is to investigate whether there is evidence that&#xD;
      panitumumab in combination with XELOX (capecitabine plus oxaliplatin) chemotherapy will&#xD;
      safely increase progression-free survival, above that of XELOX alone in subjects with KRAS&#xD;
      wild-type metastatic colorectal cancer who have not responded to or progressed after first&#xD;
      line therapy with irinotecan and a fluoropyrimidine.&#xD;
&#xD;
      Further Objectives Exploratory objectives may include investigation of potential correlations&#xD;
      between the treatment regimen and epidermal growth factor receptor (EGFR) expression,&#xD;
      detection of the functional genetic polymorphisms of the EGFR gene, EGFR gene amplification&#xD;
      (FISH), EGFR downstream protein and gene expression parameters, proteomics and epigenetics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with metastatic colorectal cancer with KRAS-wildtype will be randomized in a 1:1&#xD;
      ratio to receive a 2nd line treatment regimen of panitumumab plus oxaliplatin and&#xD;
      capecitabine (XELOX) or XELOX alone. Before randomization tumour of all subjects will be&#xD;
      analyzed to detect the KRAS mutational status. Subjects will only be randomized into these&#xD;
      two arms if the tumour shows KRAS wild-type. Subjects with KRAS mutant colorectal tumours&#xD;
      will receive XELOX alone. Subjects will receive treatment cycles every three weeks. Treatment&#xD;
      will continue until subjects are diagnosed with disease progression or intolerable toxicity,&#xD;
      at which time the subjects will be withdrawn from the treatment phase. If a subject withdraws&#xD;
      from chemotherapy due to toxicity the subjects will be allowed to continue with panitumumab&#xD;
      monotherapy with or without one of the chemotherapy components until disease progression.&#xD;
      After withdrawing panitumumab and XELOX treatment, all subjects will end the treatment phase&#xD;
      and will enter a follow-up phase until 6 months after the last patient stopped treatment&#xD;
      (with a safety follow-up visit after 56 days ± 3 days and long term follow-up visits every 12&#xD;
      weeks). During the treatment phase subjects will be evaluated for tumour response every 9&#xD;
      weeks (± one week) through to week 45, and every 12 weeks (± two weeks) thereafter, until&#xD;
      disease progression. Subjects with symptoms suggestive of disease progression should be&#xD;
      evaluated for tumour response at the time symptoms occur.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment rate to low; changed environment made protocol in its current state obsolete&#xD;
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective-response-rate</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-control-rate</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-response</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time-to-progression</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration-of-stable-disease</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time-to-treatment-failure</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall-survival</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety-endpoints</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Panitumumab + XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX (KRAS mutational status wt)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX (KRAS mutational status mutant)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Capecitabine, Panitumumab</intervention_name>
    <description>Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.&#xD;
The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.</description>
    <arm_group_label>Panitumumab + XELOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, Capecitabine</intervention_name>
    <description>The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.</description>
    <arm_group_label>XELOX (KRAS mutational status mutant)</arm_group_label>
    <arm_group_label>XELOX (KRAS mutational status wt)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 18 years or more, with histologically or&#xD;
             cytologically-confirmed and radiologically-measurable metastatic colorectal cancer.&#xD;
&#xD;
          -  One prior chemotherapy regimen for mCRC consisting of first-line fluoropyrimidine and&#xD;
             irinotecan based chemotherapy. Subjects must have disease progression (as assessed by&#xD;
             the investigator) and must be no candidates for primary metastasectomy.&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1 guidelines. All sites of disease must have&#xD;
             been evaluated within 28 days prior to registration / randomization, and diagnosed by&#xD;
             the investigator.&#xD;
&#xD;
          -  Liver and kidney function within defined ranges and sufficient bone marrow reserve.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system metastases, or significant cardiovascular disease.&#xD;
&#xD;
          -  Prior anti-EGFR antibody therapy (e.g. cetuximab) or treatment with small molecule&#xD;
             EGFR tyrosine kinase inhibitors (e.g. erlotinib).&#xD;
&#xD;
          -  Prior treatment with oxaliplatin for metastatic disease. Adjuvant therapy with&#xD;
             oxaliplatin based combination for non-metastatic disease is allowed if terminated &gt; 6&#xD;
             months prior to initiation of screening and without progression during the treatment&#xD;
             with oxaliplatin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Grunewald, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemeinschaftspraxis Hämatologie / Onkologie Im Prüfling 17-19 60389 Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIO-Studien-gGmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>July 31, 2009</study_first_submitted>
  <study_first_submitted_qc>July 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2009</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-label</keyword>
  <keyword>Phase-II-Study</keyword>
  <keyword>Randomized</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Cancer</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>Vectibix®</keyword>
  <keyword>second-line-treatment</keyword>
  <keyword>KRAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

